You are here: Industry Insights > Zai Lab

News List

Zai Lab grabs top AstraZeneca cancer executive to prep its first drug rollout fiercepharma
June 06, 2018
China’s Zai Lab is revving up for its first drug launch, and it's brought on an AstraZeneca oncology executive to lead the charge.
Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications b3cnewswire.
June 04, 2018
Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, and Crescendo Biologics Ltd (Crescendo Biologics),
Zai Lab in-licenses Entasis’s broad-spectrum antibiotic in APAC biospectrumasia
April 27, 2018
The companies will also partner on developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of serious multidrug-resistant infections caused by Acinetobacter baumannii.
China’s Zai Lab files for $115M Nasdaq IPO to take Tesaro, Bristol-Myers cancer drugs through late-p fiercebiotech
August 17, 2017
A slice of the Zai Lab IPO haul is earmarked for trials of Tesaro's niraparib.
Zai Lab raises $30 Million funding biospectrumasia
June 30, 2017
The new financing round has attracted support from both new and existing investors including blue chip US healthcare public investment funds.
Zai Lab Secures Series C Financing en-cphi.cn
June 29, 2017
Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical needs in the China market.
Paratek Pharmaceuticals and Zai Lab Team Up contractpharma
April 25, 2017
Form collaboration, development and license agreement for omadacycline in China

Previous page 1 2 Next page